𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Evidence of publication bias in clinical trials of biotherapies for solid tumors

✍ Scribed by Alessandro Ottaiano; Giuseppe Castello; Paolo Antonio Ascierto

Book ID
102106320
Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
33 KB
Volume
103
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase I clinical trial of weekly combine
Phase I clinical trial of weekly combined paclitaxel plus docetaxel in patients with solid tumors
✍ Jacob Lokich πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 70 KB πŸ‘ 2 views

A Phase I and feasibility study of combined docetaxel (D) plus paclitaxel (P) was undertaken to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) for each analogue delivered concomitantly on a weekly schedule. ## METHODS. Patients were accrued in 3-6 patient cohorts to P

Phase I clinical trial of bortezomib in
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 114 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi